2025-523759-76-01RecruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 are Tolerated and Act in the Body of Healthy Adults
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 26 Feb 2026
- Start date
- 15 Apr 2026
- Lead sponsor
- Pfizer Inc.
- EU CT number
- 2025-523759-76-01
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 100
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial studies how different amounts of the study medicine PF-08065010 are tolerated and act in the body of healthy adults.
- Age
- 18 years or older
- Sex
- All sexes
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Clinical Research Unit | Brussels | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.